Matrix gains licence to develop HPV (Human Papilloma Virus) test
This article was originally published in Clinica
Executive Summary
UK company Matrix Therapeutics has licensed from the UK Medical Research Council (MRC) exclusive global rights to certain proprietary technologies in order to develop a test for the presence of the human papilloma virus (HPV) and cervical cancer.